Marc Casper, CEO To outside observers, Marijn Dekkers’ departure from the corner office at Thermo Fisher Scientific (NYSE:TMO) might have seemed abrupt. The veteran was on a seven-year stint during which he done a profound job in re-shaping the laboratory equipment and supplies manufacturer, Thermo Fisher Scientific. But from the perspective of the company, the decision went and was taken smoothly. The main reason?— Thermo Fisher tapped long-time COO Marc Casper to take Dekkers’ place. Having joined the Company in November 2001, Casper had hold many positions inside the company and new the ‘in and outs’. He served as the Company’s Chief Operating Officer from May 2008 to October 2009 and was Executive Vice President from November 2006 to October 2009. Prior to being named Executive Vice President, he was Senior Vice President from December 2003 to November 2006. “We have an incredible group of employees at Thermo Fisher, incredibly helpful and supportive, so while the job is clearly different all of the colleagues that I’ve worked with here have stepped up and helped me make the transition. We’ve had our senior leadership taking on some of the old responsibilities I had as chief operating officer and Marijn certainly was very helpful to me as I transitioned into the CEO role,” mentions the CEO.
In the following years, the Casper created a balance in the company’s operations as nearly a quarter of their revenues came from each of its major market segments— pharmaceuticals and biotechnology, healthcare and diagnostics, and academic and government, especially in the haematology space. This, combined with its unique product mix spanning instruments, equipment, consumables, reagents and chemicals, software and services gave Thermo Fisher an industry-leading position in the haematology markets. Today, the company stands as the front-runner when it comes to delivering targeted solutions and devices in the haematology space. “Our organization has evolved over the past decade through a variety of factors including a number of interesting brands and technologies that are now offered through one entity. It is very important for us to position our brands and communicate our combined technology platforms in a simplified manner to our customers and therefore we describe each of our brands as having specific attributes that address customer needs,” states Casper.
The Dual Haematology Offering
When it comes to the haematology space, Thermo Fisher’s offerings is divided into two specific target areas, the CliniSYNC Program and Fisherbrand Hemo-Trac Blood Temperature Indicators.
CliniSYNC is a platform developed by Fisher HealthCare to address the challenges with off-site supply management. This program coordinates communication between central supply and satellite locations—clinics, urgent care sites, emergency rooms.
Thermo Fisher looks at organic as well as inorganic routes to grow. We have been investing in acquisitions that help us to enhance our offering to our customers and increase our access to growing markets worldwide
As Healthcare Reform continues to evolve, integrating physician offices and other remote locations into a healthcare integrated delivery network is critical. CliniSYNC specifically supports consistent performance and patient care in areas such as product formulary consultation, consistent system-wide pricing, uniform ordering portal, tailored delivery options, and spend analytics. CliniSYNC streamlines the supply chain across all facilities by connecting the clients’ clinics with central supply. The solution addresses challenges with offsite supply management by providing process and purchasing efficiencies, product and pricing harmonization, high-value product formulary suggestions to improve clinic testing. Here’s what a large university health system’s CEO had to say after they implemented the program, “Our teams appreciate the simplicity of ordering. I appreciate the data management and business reviews that Fisher HealthCare does for us. No other vendor comes to me with business reviews. We asked [another company] last year and they sent a print out of our orders. No strategic meetings or planning sessions. One Thermo Fisher Scientifi c for research and healthcare—and now our clinics, it just makes sense.” The Director of Materials Management of the same university health system mentions, “We enjoy using Fisher HealthCare in the hospital. Being able to order for the clinics with Fisher HealthCare enables us to save time and money. The individual account numbers with specific ship to locations all tied to our central pricing makes my job easier.”
On the other hand, Fisherbrand Hemo-Trac Blood Temperature Indicators monitors blood temperatures during storage and transport with simple press of a button. Designed for use in blood banks and transfusion services, the tool delivers quality assurance during storage or transport. Developed as a self-adhesive HEMO-Trac affixed directly to blood bag safeguards compliance, the device instantly begin monitoring core temperature of each blood bag once it is activated by push of a button. Hemo-Trac Blood Temperature Indicators also supports separate arming and breach windows insure the Hemo-Trac is correctly activated and indicates if a temperature excursion of the blood bag has occurred. Further, the device’s arming and breach system are colour coded and ensures easy readability in any situation, and also eliminates unnecessary testing of blood’s viability.
Assay Testing Stalwarts
Apart from the the CliniSYNC Program and Fisherbrand Hemo-Trac Blood Temperature, Thermo Fisher also delivers Pacific Hemostasis SickleScreen Sickling Hemoglobin Screening Kit and SickleScreen Control Set. The solution is intended toward use in screening for sickle cell disease and sickle cell trait.
SickleScreen Controls can be used with procedures based on differential solubility of reduced hemoglobin, or with enzyme immunoassays specific for Hemoglobin S. The SickleScreen Kit is a modified Nalbandian procedure based upon differential solubility. Red blood cells are lysed by a surfactant. The released hemoglobin is reduced by sodium hydrosulfite. Reduced Hemoglobin S is insoluble and forms a turbid suspension in concentrated phosphate solutions. Normal Hemoglobin A and most other hemoglobins remain in solution under these conditions. Both sickle cell disease and sickle cell trait can be detected with this procedure.
"We’ve had our senior leadership taking on some of the old responsibilities I had as chief operating officer and Marijn certainly was very helpful to me as I transitioned into the CEO role"
Fisherbrand SickleScreen products use a modified Nalbandian procedure that provides fast and accurate results for screening and detecting hereditary sickle cell disease and sickle cell trait. When sickle cell patients are in crisis, their Hb S becomes sickle or cresent shaped and can no longer carry oxygen. The abnormal cells often break apart and can cause damage to the spleen, kidneys, bone, eyes, lungs and central nervous system. The procedure is based on the differential solubility of Hemoglobin S (Hb S) and Hemoglobin A (Hb A) in concentrated phosphate solution. While the 120-test kit contains phosphate buffer (4 x 125mL) and four sodium hydrosulfite vials, the 30-test kit contains a bottle of phosphate buffer (125mL) with a dispensing cap and 30 pre-filled reaction vials.
A Massachusetts Company
Being one of the larger companies in Massachusetts and we’re very committed to the community, Thermo Fisher has indeed carved a unique niche in the haematology marketplace. Casper believes that Massachusetts has brought good fortunes for the company as they look to grow further. “Not only is our headquarters here, but a number of our divisions are headquartered in the Bay State. It’s been a good environment for us. There’s a good pool of talent here. The access to the research institutions, the access to the great universities here and the great medical centers, makes it an area that is a good place to interact in our field,” he says. As a company which has witnessed more ups and less downs, for Thermo Fisher acquiring talented people and companies will be the road toward the future success. “Thermo Fisher looks at organic as well as inorganic routes to grow. We have been investing in acquisitions that help us to enhance our offering to our customers and increase our access to growing markets worldwide,” Casper mentions.
Meanwhile, the company will stay rooted in Massachusetts. “Although the cost of living is high and therefore certain jobs are going to fit more easily here than others, and that’s a challenge, and the tax situation and so forth is a challenge, but we’ve found the benefits of the talent pool here and the access to customers and thought leaders has outweighed some of the challenges that others might have raised,” informs Casper. “As a company we worry about education. We want to make sure the next generation and the generations thereafter of scientists are growing up in our community, and we’re trying to put some emphasis on being helpful in that regard.”
- Shiv Shanker March 01, 2019
Thermo Fisher Scientific (NYSE:TMO) News
Thermo Fisher Scientific to Acquire Brammer Bio
Thermo Fisher Scientific launches Innovative products at Pittcon 2019
This content is copyright protected
However, if you would like to share the information in this article, you may use the link below: